From the Robert M. Berne Cardiovascular Research Center (R.A.B., G.K.O.), Department of Biochemistry and Molecular Genetics (R.A.B.), and Department of Molecular Physiology and Biological Physics (G.K.O.), University of Virginia, Charlottesville; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (D.G.), Division of Cardiology, University of Pittsburgh School of Medicine, PA (D.G.); Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center, France (Z.M.); and Laboratory of Clinical Chemistry, University Medical Centre Utrecht, The Netherlands (G.P.).
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):e174-e177. doi: 10.1161/ATVBAHA.117.310097. Epub 2017 Sep 28.
The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.
CANTOS 试验的结果为支持人类动脉粥样硬化炎症假说提供了令人兴奋的证据，也是首个显示靶向抗炎治疗临床获益的 III 期临床试验。然而，整体临床获益有限，以及增加致命感染易感性的安全性担忧表明，我们在这一关键领域还需要做更多的工作。
